Loading...
Please wait, while we are loading the content...
Similar Documents
PLK1 as a potential prognostic marker of gastric cancer through MEK-ERK pathway on PDTX models
| Content Provider | Scilit |
|---|---|
| Author | Dang, Sheng-Chun Fan, Yi-Yi Cui, Lei Chen, Ji-Xiang Qu, Jian-Guo Gu, Min |
| Copyright Year | 2018 |
| Description | PLK1 as a potential prognostic marker of gastric cancer through MEK-ERK pathway on PDTX models Sheng-Chun Dang,1 Yi-Yi Fan,1 Lei Cui,1 Ji-Xiang Chen,1 Jian-Guo Qu,1 Min Gu2 1Department of General Surgery, The Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu Province, People's Republic of China; 2Zhenjiang Integrative Medicine Hospital, Zhenjiang, Jiangsu Province, People's Republic of China Background: PLK1 has been identified as having a great effect on cell division and maintaining genomic stability in mitosis, spindle assembly, and DNA damage response by current studies. Materials and methods: We assessed PLK1 expression in cervical cancer tissues and cells. We have also evaluated the effects of PLK1 on gastric cancer cell proliferation, migration, and apoptosis both in vitro and in vivo. Results: Our results show that PLK1 is overexpressed in gastric cancer tissues and cells. Inhibition of PLK1 contributes cell cycle G2-phase arrest and inhibits the proliferation, migration, and apoptosis of gastric cancer (GC) cells, whereas its overexpression promotes proliferation, migration, and apoptosis in these cells. Moreover, PLK1 inhibition reduces expression of pMEK and pERK. More importantly, in vivo by analyzing tumorigenesis in patient-derived tumor xenograft (PDTX) models, the inhibition of PLK1 activity by BI6727 significantly decreased the volume and weight of the tumors compared with control group (P<0.01). Conclusion: Our results found that PLK1 has a significant impact on the survival of GC cells; it may become a prognostic judge, a potential therapeutic target, and a preventative biomarker of GC. Keywords: gastric cancer, PLK1, cell cycle, apoptosis, MEK/ERK pathway, patient-derived tumor xenografts |
| Related Links | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6163028/pdf https://www.dovepress.com/getfile.php?fileID=44708 |
| Ending Page | 6247 |
| Page Count | 9 |
| Starting Page | 6239 |
| ISSN | 11786930 |
| DOI | 10.2147/ott.s169880 |
| Journal | OncoTargets and therapy |
| Volume Number | 11 |
| Language | English |
| Publisher | Informa UK Limited |
| Publisher Date | 2018-09-01 |
| Access Restriction | Open |
| Subject Keyword | Journal: Oncotargets and Therapy Integrative and Complementary Medicine Mek/erk Pathway Plk1 Apoptosis Cell Cycle Gastric Cancer Patient-derived Tumor Xenografts |
| Content Type | Text |
| Resource Type | Article |
| Subject | Pharmacology (medical) Oncology |
